Proteins and Peptides
13 January 2015
Capricor Therapeutics Initiates the DYNAMIC Clinical Trial for the Treatment of Advanced Heart Failure12 January 2015
Hospira Submits New Biologics License Application to U.S. FDA for Proposed Epoetin Alfa Biosimilar8 January 2015
Versartis Initiates Global Phase 3 Study of VRS-317 in Children With Growth Hormone Deficiency8 January 2015
Sandoz biosimilar filgrastim recommended for approval by FDA Oncologic Drugs Advisory Committee7 January 2015
Zafgen Announces Positive Results From Phase 2 Clinical Trial of Beloranib in Hypothalamic Injury Associated Obesity5 January 2015
Revance Therapeutics Announces Initiation of BELMONT Phase 2 Active Comparator Trial of Injectable RT0025 January 2015
Soligenix Announces Positive Preliminary Nonclinical Results in Macrophage Activation Syndrome30 December 2014
Alexion Completes Rolling BLA Submission to U.S. FDA for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia29 December 2014
Palatin Announces Start of Bremelanotide Phase 3 Program For Female Sexual Dysfunction29 December 2014
Recombinant coagulation factors: market, products, R&D pipeline and new competition from alternative procoagulants and gene and cell therapy23 December 2014
ContraFect Receives FDA Approval to Initiate Clinical Trials of CF-301 for MRSA Bloodstream Infections23 December 2014
Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection22 December 2014
Baxter Submits Application for U.S. FDA Approval of BAX111, Investigational Recombinant Treatment for Von Willebrand Disease22 December 2014
Sobi’s Xiapex receives positive opinion by CHMP for the treatment of Peyronie’s disease20 December 2014
Jazz Pharmaceuticals Receives FDA Approval For Intravenous Administration Of Erwinaze® (asparaginase Erwinia chrysanthemi)19 December 2014
Tresiba® receives positive opinion from CHMP for treatment of children with diabetes18 December 2014
D-Pharm Achieves Primary End-point in Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated With tPA18 December 2014
First Patient Treated in Mapi Pharma’s Phase IIa Clinical Trial of GA Depot for Relapsing Remitting Multiple Sclerosis (RRMS)News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports